Post by Grünenthal Group

We announced the successful completion of a Phase I trial evaluating the safety and tolerability profile of our proprietary nociceptin receptor (NOP) agonist today. In the trial, which involved 113 healthy participants, our investigational compound was demonstrated to be safe and well tolerated, with no dose-dependent adverse event pattern observed. A Phase II trial will commence later this year to evaluate the efficacy and safety of our compound for the treatment of acute pain as we pursue our goal to identify new mechanisms of action in the therapeutic area of pain. If approved, our NOP agonist could be providing patients with a first-in-class therapy option. Learn more about our selective NOP agonist: https://bit.ly/4v2fbdy #WorldFreeofPain #WeAreGrünenthal #ClinicalDevelopment